

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 73474

**Title:** Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/ microsatellite-stable type endometrial cancer: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05486871

**Position:** Peer Reviewer

**Academic degree:** Doctor, PhD

**Professional title:** Academic Research, Lecturer, Physiotherapist

**Reviewer's Country/Territory:** Turkey

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-11-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-12-11 05:40

**Reviewer performed review:** 2021-12-11 07:28

**Review time:** 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

## **SPECIFIC COMMENTS TO AUTHORS**

I read and reviewed the article entitled “A case study of PD-1 inhibitor combination treatment for recurrent pMMR/MSS-type endometrial cancer”. Abstract: “Endometrial cancer is one of the most common cancers of the female reproductive tract and its worldwide incidence has gradually increased over the past decades. PD-1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block PD-1 and PD-L1 activities on the cell surface to prevent immune escape.” These two sentences should be taken as too detailed information for the abstract. Introduction: “This article includes a case study and preliminary discussion of PD-1 inhibitor immunotherapy combined with chemotherapy or anti-angiogenesis targeted therapy for a patient with pMMR/MSS recurrent EC; we further elaborate the molecular classification, choice of treatment regimen, and therapeutic efficacy.” The authors should use “presents” term instead of “includes”. Case Presentation: “. Four years later, she developed chest pain”. Pain severity, type (e.g., sharp, burning) should be given, if questioned.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 73474

**Title:** Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/ microsatellite-stable type endometrial cancer: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 00183481

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-11-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-12-12 23:11

**Reviewer performed review:** 2021-12-20 11:40

**Review time:** 7 Days and 12 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

## SPECIFIC COMMENTS TO AUTHORS

Zhai C et al. presented a case report of a patient with pMMR/MSS endometrial cancer treated with combination of a PD-1 inhibitor and a tyrosine kinase inhibitor. The authors have previously reported the efficacy and safety of the combination treatment for non-small cell lung cancer (Front Oncol 2021). A recurrent endometrial cancer after chemotherapies were treated with a novel PD-1 inhibitor toripalimab. Eventually the combination of the PD-1 inhibitor and a tyrosine kinase inhibitor, anlotinib successfully diminished lung metastasis. The characteristics of the metastatic tumor, analyses with immunohistochemistry and genetic sequencing, were confirmed pMMR and MSS-type endometrial adenocarcinoma. This case report indicates the regime combined with a PD-1 inhibitor and a tyrosine kinase inhibitor may be effective against pMMR/MMS endometrial cancer. This well-written manuscript can be published with some minor revisions. Minor points 1. The graph in Figure 3 should be ranged from 2019 to 2021. 2. In Figure 4, treatments are indicated with arrows. The terms can be shown with rectangles or other. 3. In figure legend of Fig 2, 4/16/2020 may be a typographical error.